BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth

Key Takeaways BHC shares fell after Q4 EPS missed estimates despite 9% revenue growth and a top-line beat.BHC's Salix and International units drove gains, with Xifaxan sales up 10% year over year.BHC guided 2026 revenues to $10.625-$10.875B, above consensus expectations.Bausch Health Companies Inc. (BHC) reported mixed results for the fourth quarter of 2025. Consequently, shares are trading down in after-hours trading.Adjusted earnings per share (EPS) of $1.08 missed the Zacks Consensus Estimate of $1.21 bu ...